TickerTalks
Browse all tickers →
TickerTalks›$ZYBT
ZYZYBT

Zhengye Biotechnology Holding Limited

$ZYBT·$59M·Drug Manufacturers - Specialty & Generic·Healthcare
$1.42-2.1%YTD+21.2%1Y-45.1%
Price updated 13m ago·X counts updated 9d ago
ZYZYBT
$ZYBTZhengye Biotechnology Holding Limited
$1.42-2.07%113 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $ZYBT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

113X posts · last 7 days
Oct 2Oct 11
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $ZYBT's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 84% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-08-01

ZYBT chatter is uniformly bullish day-trader momentum content. Retail traders claim a call at $1.20 that hit $11.40 for +850% - part of a broader July run for microcap momentum names alongside CPHI ($3 → $19.19, +539%), ADVB ($6.30 → $25.84), STAK, DFNS and STKH. Some holders got stuck in halts (-$27k blowup cited). Momentum-scan chatter groups ZYBT with other 'China's' JLHL, ZCMD, PN.

Read what X is saying about $ZYBT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ZYBT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storyWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Zhengye Biotech is a thin-float Chinese animal-vaccine microcap trading on day-trader squeezes — not an institutional security.

Zhengye Biotechnology Holding is one of the clearest examples of a thin-float Chinese microcap caught in the July 2026 micro-cap squeeze cycle — retail traders claimed $1.20-to-$11.40 runs (+850%) in July alongside CPHI, ADVB, STAK, DFNS, and STKH.

  • The 4.4M-share float plus -2.5 beta describe a pure trader instrument; the July 21 'unusual trading activity' comment from management plus the August 6 Nasdaq minimum bid-price compliance regain confirm the squeeze dynamics without any underlying operational catalyst.
  • The animal-health vaccine business for Chinese agricultural swine, bovines, and goats is real but tiny — Q4 2025 revenue of $53M versus the $59M market cap says the equity is trading at distressed valuations in cost-of-capital terms.
  • At $1.22 and 8% of the 52-week range after a 51% twelve-month decline, the stock is pricing continued illiquidity and uncertainty; sell-side has zero coverage and no earnings date.

For an institutional investor, this is a watch-only name; the thin-float squeeze dynamics are not an investment thesis, and the underlying Chinese animal-health business is not large enough to support institutional accumulation at this scale.

Agrees with X sentimentX is bullish on the day-trader momentum story and comparisons to other microcap momentum names; the TickerTalks read agrees — this is a thin-float trading instrument rather than a fundamental investment.

What to watch: Any Nasdaq compliance update and listing-status change; any strategic alternatives announcement; next quarterly or semi-annual reporting cadence from the Chinese animal-health business.

On the calendar: Earnings date not yet announced

thin coverage

Read the AI verdict on $ZYBT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Chinese animal vaccine manufacturer supplying swine, poultry, and livestock immunizations domestically and exporting to Southeast Asia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $ZYBT.

Drug Manufacturers - Specialty & Generic · Healthcare

Specialty pharma is bifurcating — GLP-1 adjacent programs attract premium valuations while generic manufacturers face pricing erosion from FDA approval backlogs clearing. Biosimilar launches of adalimumab (Humira), ustekinumab, and etanercept are accelerating branded erosion timelines, while mid-tier specialty pharma focuses on complex generics (ophthalmic, inhalation) to sustain margins.

What this means for $ZYBT

Neutral — Chinese animal vaccine manufacturer supplying swine, poultry, and livestock immunizations domestically and exporting to Southeast Asia.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+34.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-36.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-16.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-77.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
32.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
8.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$53.0M—8.3%-77.0%$-0.98$25.8M
Q3 FY25$27.0M—8.3%-77.0%$-0.51$13.3M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.11%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-4.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+26.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 4.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-2.295-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 253
AI summary

Han Zhenfa, Director and 10%+ owner of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing indirect beneficial ownership of 42,963,748 ordinary shares across three BVI holding entities: 40,000,000 shares via Securingium Holding Limited (held through a family trust of which Han is settlor, beneficiary, and protector), 2,278,752 via Vanguards Skyline Holdings Limited, and 684,996 via VVAX Holdings Limited. This is a material 10%+ owner disclosure revealing a concentrated, multi-entity controlling stake typical of a founder/principal investor in a recently listed Chinese biotech.

3New insider — initial holdingsJun 253
AI summary

Cheng Yuhong, Vice General Manager of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing no beneficially owned securities. This is a routine SEC Section 16 compliance filing required upon becoming an officer of a reporting company; no ownership position or investment activity is reported.

3New insider — initial holdingsJun 253
AI summary

Song Songlin, Co-Chief Executive Officer of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing no beneficially owned securities. Routine Section 16 compliance filing by an executive officer; no ownership position or investment activity reported.

3New insider — initial holdingsJun 253
AI summary

Wang Ping, Chief Financial Officer of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing no beneficially owned securities. This is a routine Section 16 compliance filing required upon becoming an officer of a public company; no ownership position or investment activity is reported.

3New insider — initial holdingsJun 253
AI summary

Jiang Ping, Director of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing no beneficially owned securities. Routine Section 16 compliance filing by a director; no ownership position or investment activity reported.

3New insider — initial holdingsApr 243
3New insider — initial holdingsApr 243
+ 4 other (3 6-Ks · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirementglobenewswire.com·75d agoZhengye Biotechnology Holding Limited Comments on Unusual Trading Activityglobenewswire.com·91d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$PCRX$TEVA$ACB$ZTS$ELAN$EVO$INDV$EBS
Voices on X · last 7 days

No standout posts about $ZYBT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport